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Purpose: To investigate the relationship between transforming growth factor beta-1 (TGF-β1) and interleukin-6 (IL-6)
in human trabecular meshwork (HTM) cells as well as to identify the signaling pathway/s involved in the increased IL-6
expression that occurs in response to mechanical stress and TGF-β1.
Methods: All experiments were performed in confluent monolayers of HTM cells at passage 3. Secreted IL–6 was
quantified by ELISA. Levels of IL-6 mRNA were evaluated by polymerase chain reaction (PCR) analysis. Activation of the
IL-6 and TGF-β1 promoters was monitored by measuring secreted alkaline phosphatase protein (SEAP) released into the
culture medium by HTM cells infected with an adenovirus expressing the SEAP reporter gene that was controlled by either
the IL-6 promoter (AdIL6–SEAP) or the TGF-β1 promoter (AdTGFβ1-SEAP). Cyclic mechanical stress (5% elongation,
one cycle per second) was applied using the Flexcell System. Reagents used in this study included human TGF–β1, human
IL-6, and the inhibitors for the p38 mitogen-activated protein kinase (MAPK; SB202190), c-jun NH2-terminal kinase
(JNK; SP600125), extracellular-regulating kinase (ERK; PD98059), and TGF type I activin receptor (SB431542).
Results: Incubation of HTM cells with TGF–β1 (5 ng/ml) resulted in a significant increase in the protein and mRNA
levels  of  IL-6,  which  was  significantly  diminished  in  the  presence  of  the  inhibitors  for  p38  MAPK  or  JNK.  No
transcriptional activation of the exogenous IL-6 promoter was observed following TGF-β1 treatment. In addition, the
presence of inhibitors for the p38 MAPK, ERK, and TGF-β1 pathways significantly decreased the increased expression
of  IL-6  by  cyclic  mechanical  stress.  Furthermore,  exposure  of  HTM  cells  to  IL-6  (100  ng/ml)  demonstrated  the
transcriptional activation of TGF-β1 promoter, which was severely impaired by blocking the p38 MAPK pathway.
Conclusions: Our results indicate that TGF-β1 participates in the regulation of basal expression and the stretch-induced
expression of IL-6 and suggest the possible existence in cultured HTM cells of an autocrine loop between IL-6 and TGF-
β1. We also found that p38 MAPK might play a contributing role in the maintenance of such a loop.
The  conventional  outflow  pathway,  composed  of  the
trabecular  meshwork  (TM)  and  Schlemm's  canal  (SC),
constitutes the main route by which the aqueous humor (AH)
exits the anterior chamber of the eye, and it is the tissue
primarily  responsible  for  maintaining  proper  levels  of
intraocular pressure (IOP) [1]. The functional failure of the
TM/SC outflow pathway is believed to cause the elevation of
IOP commonly associated with primary open-angle glaucoma
(POAG) [2,3]. It has been hypothesized that the TM/SC tissue
may respond to transient changes in IOP by altering its AH
outflow resistance [4-7], thus maintaining normal IOP levels.
However,  the  molecular  and  physiologic  mechanisms
regulating such potential outflow pathway tissue homeostasis
are far from being understood.
Our laboratory has long hypothesized that mechanical
stress accompanying the elevated IOP-associated changes in
outflow pathway morphology induces the release from TM
cells of factors that might act in a homeostatic, regulatory
manner to increase outflow facility and lower IOP by either
altering the conductivity of SC or changing the geometry of
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the TM pathway for aqueous flow. Supporting this hypothesis,
we have demonstrated that exposure of TM cells to cyclic
mechanical  stress  induces  the  expression  of  transforming
growth factor beta-1 (TGF-β1) and interleukin-6 (IL-6) in
human trabecular meshwork (HTM) cell primary cultures as
well as organ cultures of porcine anterior segments [8,9]. We
additionally found that IL-6 increases outflow facility when
administered  to  porcine  perfused  anterior  segments.
Furthermore,  our  studies  revealed  that  TGF-β1  itself
upregulated the expression of IL-6 in HTM cells, suggesting
that  the  initial  activation  of  TGF-β1  may  be  one  of  the
contributing factors leading to the induction of IL-6 [8,9]. The
molecular mechanisms participating in these inductions are
unknown.
Mitogen-activated protein kinases (MAPKs) are a family
of serine/threonine-specific protein kinases that respond to
extracellular stimuli and regulate various cellular activities
such  as  gene  expression,  mitosis,  differentiation,  and  cell
survival/apoptosis.  Three  MAPKs  have  been  identified  in
mammalian cells, the extracellular-regulating kinase (ERK),
the c-jun NH2-terminal kinase (JNK), and the p38 MAPK.
MAPK  signaling  pathways  have  been  implicated  in  the
expression of cytokines in response to other stimuli [10,11].
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326Herein, we aimed at further exploring the relationship
between  TGF-β1  and  IL-6  in  HTM  cells  as  well  as  at
identifying the signaling pathway/s involved in the increased
IL-6 expression in response to mechanical stress and TGF-
β1. The data presented in this study suggest the existence of
an autocrine loop between TGF-β1 and IL-6 in cultured HTM
cells and that p38 MAPK might play a pivotal role in the
maintenance of such a loop.
METHODS
Reagents: Recombinant human TGF-β1 and IL-6 proteins
were purchased from Sigma (St. Louis, MO). SB202190 (p38
MAPK inhibitor), PD98959 (mitogen activated protein kinase
kinase  1  [MEK1]  inhibitor),  SP600125  (JNK  inhibitor),
SB431542  (TGF  type  I  activin  receptor  inhibitor),  and
actinomycin D were obtained from Sigma.
Cell  cultures:  Primary  cultures  of  human  TM  cells  were
prepared from cadaver eyes (ages 30–60) obtained less than
48 h post-mortem from donors with no history of eye disease
as previously described [12] and were maintained at 37 °C in
5% CO2 in low glucose Dulbecco’s Modified Eagle Medium
(DMEM) with L-glutamine and 110 mg/l sodium pyruvate
supplemented with 10% fetal bovine serum (FBS), 100 μM
non-essential amino acids, 100 units/ml penicillin, 100 μg/ml
streptomycin sulfate, and 0.25 μg/ml amphotericin B. All the
reagents  were  obtained  from  Invitrogen  Corporation
(Carlsbad,  CA).  All  experiments  were  performed  in  the
absence of serum. Cultures were serum-withdrawn for 16 h
before the experiment.
Measurement  of  IL-6  concentration:  The  levels  of  IL-6
protein released to the culture medium were quantified with a
commercially  available  sandwich  enzyme-linked
immunoassay kit (Biosource International, Camarilla, CA)
according to the manufacturer’s instructions.
Cyclic mechanical stress application in cell culture: Primary
cultures of HTM cells at passage 3 were plated on type I
collagen-coated  flexible  silicone  bottom  plates  (Flexcell,
Hillsborough, NC). Once confluence was reached, culture
medium was switched to serum-free DMEM, and cells were
subjected  to  cyclic  mechanical  stress  (5%  stretching,  one
cycle per second) for the indicated times in each experiment,
using  the  computer-controlled,  vacuum-operated  FX-3000
Flexercell Strain Unit (Flexcell, Hillsborough, NC). Control
cells  were  cultured  under  the  same  conditions,  but  no
mechanical force was applied.
Quantitative real-time polymerase chain reaction (qPCR):
Total RNA from HTM primary cultures was isolated using
RNeasy  kit  (Qiagen  Inc.,  Valencia,  CA)  following  the
manufacturer’s protocol and then treated with DNase. RNA
yields were determined using the RiboGreen® fluorescent
dye (Molecular Probes Inc., Eugene, OR). First strand cDNA
was  synthesized  from  total  RNA  (1  µg)  by  reverse
transcription  using  oligo(dT)  primer  and  Superscript  II
reverse transcriptase (Invitrogen, Carlsbad, CA) according to
the manufacturer’s instructions. Real-time polymerase chain
reaction (PCR) reactions were performed in a 20 μl mixture
containing 1 µl of the cDNA preparation, 1X iQ SYBR Green
Supermix  (Bio-Rad,  Hercules,  CA),  and  500  nm  of  each
primer in the Bio-Rad iCycler iQ system (Bio-Rad, Hercules,
CA) using the following PCR parameters: 95 °C for 5 min
followed by 50 cycles of 95 °C for 15 s, 65 °C for 15 s, and
72 °C for 15 s. The fluorescence threshold value (Ct) was
calculated using the iCycle iQ system software (Bio-Rad).
Differential fold expression was calculated using the equation,
2-ΔΔCt,  where  ΔΔCt=ΔCtexperimental−ΔCtcontrol  condition  and
ΔCt=Ctgene–CtAct. The absence of nonspecific products was
confirmed by both the analysis of the melt curves and by
electrophoresis  in  3%  Super  AcrylAgarose  (DNA
Technologies,  Gaithersburg,  MD)  gels.  β-Actin,  whose
expression remained unchanged during all the experimental
conditions  (Figure  1),  served  as  an  internal  standard  for
mRNA expression. The sequences of the primers used for the
amplifications were: IL6 F 5′-CAA ATT CGG TAC ATC
CTC GAC GGC-3′, IL6 R 5′ GGT TCA GGT TGT TTT CTG
CCA GTG C-3′, β-Actin F 5′-CCT CGC CTT TGC CGA TCC
G-3′, β-Actin R 5′-GCC GGA GCC GTT GTC GAC G-3′.
SEAP  reporter  gene  assay:  HTM  primary  cultures  were
infected with 20 pfu/cell of either of the replication-deficient
recombinant adenoviruses, AdIL6-SEAP [9] or AdTGFβ1-
SEAP  [8],  which  expresses  the  reporter  gene,  secreted
alkaline phosphatase protein (SEAP), under the control of
either the IL-6 gene promoter (−1168/+3 region [13]) or the
TGF-β1 gene promoter (−453/+11 region [14], ), respectively.
Activation  of  exogenous  IL-6  or  TGF-β1  promoters  was
quantified by determining the amount of the SEAP released
to the culture medium through the use of the Great EscAPeTM
SEAP  chemiluminescence  detection  kit  (BD  Biosciences
Clontech, Palo Alto, CA) according to the manufacturer’s
protocol.
Statistical  analysis:  All  the  experiments  were  repeated  in
triplicate in independent experiments using three different
HTM cell lines. Data are represented as mean±SD. Statistical
significance  between  groups  was  assessed  by  the  paired
Student's t-test. A value of p<0.05 was considered statistically
significant.
RESULTS
Effect of TGF-β1 on IL-6 expression in human trabecular
meshwork primary cultures: To better characterize the TGF-
β1 stimulatory effect on IL-6 secretion in HTM cells, we
treated three different cultures of HTM cells with exogenous
TGF-β1 in the absence of serum. The amount of TGF-β1 (5
ng/ml) used in these experiments was based on our previous
study [9]. To not cause any additional stress, HTM cultures
were allowed to equilibrate in serum-free media for 16 h
before the addition of the cytokine.
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327As shown in Figure 2A, exogenous TGF-β1 significantly
produced an accumulation of secreted IL-6 in the culture
media at 6 h (378.09±33.84 pg/ml IL-6 in treated cultures
versus  206.7±62.01  pg/ml  IL-6  in  non-treated  cultures,
p=0.0137)  and  at  16  h  (1,137.89±85.29  pg/ml  versus
387.67±10.22 pg/ml, p=0.0001) post TGF-β1 treatment. The
upregulated  production  of  IL-6  in  response  to  TGF-β1
treatment  was  markedly  suppressed  in  the  presence  of
SB431542, a TGF type I activin receptor inhibitor (Figure 2B;
1,014.12±128.36 pg/ml versus 613.2±78.1 pg/ml, p=0.004).
Moreover,  basal  IL-6  secretion  was  also  downregulated
(Figure  2B;  405.63±87.1  pg/ml  versus  137.9±52.3  pg/ml,
p=0.01), indicating that endogenous TGF-β1 participates in
the regulation of IL-6 expression in HTM cells.
Quantification  of  IL-6  mRNA  by  qPCR  showed  a
progressive increase in IL-6 mRNA concentrations following
TGF-β1 treatment, which reached a peak at 6 h (1.80±0.088
fold, p=0.0001), and then declined to control levels after 16
h. It is noteworthy that IL-6 mRNA levels decreased in the
untreated cultures over time (Figure 2C).
To  investigate  whether  elevated  IL-6  expression
following TGF-β1 treatment is associated with increased IL-6
gene transcription, we examined the effect of TGF-β1 on IL-6
promoter activity in HTM cells infected with AdIL6-SEAP.
As shown in Figure 2D, TGF-β1 did not exert any significant
effect on exogenous IL-6 promoter activity in HTM cultures.
Moreover, increased levels of IL-6 mRNA following TGF-
β1 treatment were observed in the presence of the transcription
inhibitor, actinomycin D (4 μg/ml; Figure 2E).
Effect of MAPK on the TGF-β1 induced expression of IL-6:
We next examined the intracellular signaling pathway through
which TGF-β1 stimulates IL-6 expression and secretion by
HTM cells. For this, three different cultures of HTM cells that
were serum-deprived for 16 h were pre-treated for 2 h with
either p38 inhibitor (SB 202190, 10 μM), MEK1 inhibitor
(PD98059, 10 μM), or JNK inhibitor (SP600125, 10 μM) and
then exposed to TGF-β1 (5 ng/ml) in the presence of the
Figure  1.  β-Actin  mRNA  expression.
(A)  β-Actin  mRNA  expression,
expressed as a function of the Ct value,
in HTM cells exposed to TGF-β1 (5 ng/
ml)  treatment  during  the  indicated
times. (B) β-Actin mRNA expression in
HTM  cells  subjected  to  cyclic
mechanical stress and MAPK inhibitors.
Statistical significance between groups
was assessed by the paired Student's t-
test (n=3).
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328inhibitors. As shown in Figure 3, pre-treatment of HTM with
the p38 MAPK inhibitor led to a significant decrease in the
TGF-β1  induced  expression  of  IL-6  at  both  the  protein
(513.43±72.53  pg/ml  secreted  IL-6  in  SB202190-treated
cultures  versus  996.41±166.19  pg/ml  in  vehicle-treated
cultures, p=0.009) and mRNA levels (1.31±0.37 fold IL-6
mRNA  expression  in  SB202190-treated  cultures  versus
3.03±0.67  fold  in  vehicle-treated  cultures,  p=0.017),
quantified at 16 h and 6 h, respectively. Our results also
showed a significant reduction in the levels of secreted IL-6
induced by TGF-β1 with the JNK inhibitor (474.41±55.68 pg/
ml  secreted  IL-6  in  SP600125-treated  cultures  versus
996.41±166.19 pg/ml in vehicle-treated cultures, p=0.007;
Figure 3A). Although it did not reach statistical significance,
IL-6 mRNA was found to be downregulated with SP600125
(2.1±0.5 IL-6 mRNA fold expression in SP600125-treated
cultures  versus  3.03±0.67  fold  in  vehicle-treated  cultures,
p=0.126). These data indicate a role of p38 MAPK and JNK
pathways in IL-6 induction by exogenous TGF-β1.
Effect  of  TGF-β1  and  MAPKs  on  the  stretch-induced
expression  of  IL-6:  Our  laboratory  previously  reported
increased IL-6 expression in HTM cells subjected to cyclic
mechanical  stress  [8,9].  To  characterize  the  signaling
mechanisms by which mechanical stress upregulates IL-6 in
HTM cells, we pre-treated three different cultures of HTM
cells, which were serum-starved for 16 h, with 10 μM of either
SB202190 (p38 inhibitor), PD98059 (MEK1 inhibitor), or
SP600125  (JNK  inhibitor)  for  2  h.  Cultures  were  then
subjected to cyclic mechanical stress (5% elongation, one
cycle/second).  As  discussed  elsewhere  [8,9],  this  stretch
regime was selected as an in vitro model to mimic the pulsatile
mechanical forces to which TM are normally exposed [15,
16]. Blocking the p38 or ERK pathway caused a significant
decrease in the induction of IL-6 by mechanical stress at both
the  protein  (1,012.18±67.79  pg/ml  with  vehicle  versus
458.6±142.74 pg/ml and 584.29±45.63 pg/ml with SB202190
and  PD98059,  respectively,  p<0.005)  and  mRNA  levels
(1.61±0.22  fold  with  vehicle  versus  0.66±0.22  fold  and
0.75±0.38 fold with SB202190 and PD98059, respectively,
p<0.05; Figure 4). Although some effect was also observed in
the presence of SP600125, it varied among the different cell
lines used in the study, suggesting that although it might
participate somehow, JNK does not play a crucial role in the
upregulation of IL-6 mediated by mechanical stress.
We were also interested in investigating whether TGF-
β1 might be involved in the stretch-induced expression of
Figure  2.  Effect  of  TGF-β1  on  IL-6
expression  in  human  trabecular
meshwork  primary  cultures.  Three
independent primary cultures of HTM
cells were serum-starved for 16 h and
then incubated in serum-free media with
TGF-β1 (5 ng/ml). A: Levels of secreted
IL-6 quantified by ELISA are shown.
B: Levels of secreted IL-6 in cultures
pre-treated  with  the  TGFRI  inhibitor
(SB431542) before TGF-β1 treatment is
shown in the chart. C: Differential IL-6
mRNA  expression  compared  to  the
control at 3 h is shown. D: HTM cells
were  infected  with  AdIL6-SEAP
(m.o.i=20  pfu/cell).  At  day  1  post-
infection, cells were serum-starved for
24 h and then incubated in serum-free
media with TGF-β1 (5 ng/ml). SEAP
activity was assayed in the culture media
at the indicated times. E: Differential
IL-6 mRNA expression of HTM cells
that  were  exposed  to  TGF-β1  in  the
presence of actinomycin D (4 μg/ml) is
shown. The asterisk indicates that p is
less  than  0.05,  and  a  double  asterisk
denotes  that  p  is  equal  to  0.001.
Statistical significance between groups
was assessed by the paired Student's t-
test (n=3).
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329IL-6. For this purpose, we chemically blocked the TGF-β1
pathway using an inhibitor of the TGF type I activin receptor
(SB431542,  10  μM).  As  shown  in  Figure  4,  chemical
inhibition of the TGF-β1 pathway clearly led to a significant
decrease  in  the  levels  of  both  secreted  IL-6  protein
(1,012.18±67.79 pg/ml secreted IL-6 in stretched vehicle-
treated  cultures  versus  256.27±57.6  pg/ml  in  stretched
SB431542-treated cultures, p=0.0001) and mRNA content
(1.61±0.22 IL-6 mRNA fold expression in  stretched vehicle-
treated cultures versus 0.89±0.17 fold in stretched SB431542-
treated cultures, p=0.01) induced by cyclic mechanical stress.
These data complement our previous observation showing
diminished stretch-induced IL-6 production in the presence of
neutralizing antibodies against TGF-β1 [9].
Effect of IL-6 on the TGF-β1 promoter activity: Several works
have reported a cross talk between IL-6 and TGF-β1 signaling
pathways  in  different  cell  lines  [17-20].  We  wondered
whether IL-6 might upregulate TGF-β1 expression in HTM
cells and thus initiate an autocrine loop similar to the one
described in activated pancreatic stellate cells [21]. For this
purpose, we treated three different HTM primary cultures
previously  infected  with  the  recombinant  adenovirus,
AdTGFβ1-SEAP,  with  IL-6  (100  ng/ml).  Such  IL-6
concentration, which significantly increased the permeability
of SC endothelial cells as well as outflow facility in perfused
porcine  anterior  segments  [9],  has  been  used  for  similar
studies  in  other  cell  types  [17].  As  shown  in  Figure  5A,
exogenous IL-6 quickly induced the transcriptional activation
of TGF-β1 promoter at 3 h (112.79±33.4 relative fluorescence
Figure 3. Effect of MAPK on the TGF-β1 induced expression of IL-6. Three independent primary cultures of HTM cells were serum-starved
for 16 h, pre-treated for 2 h with the MAPK inhibitors, and then incubated in serum-free media with TGF-β1 (5 ng/ml) in the presence of the
MAPK inhibitors (10 μM). A: Secreted IL-6 quantified by ELISA at 16 h post-treatment is shown. B: Differential IL-6 mRNA expression
compared to control-DMSO, calculated at 6 h post-treatment. The asterisk indicates that p is greater than 0.001, and a double asterisk denotes
that p is less than 0.001. Statistical significance between groups was assessed by the paired Student's t-test (n=3).
Figure 4. Effect of TGF-β1 and MAPKs on the stretch-induced expression of IL-6.Three independent primary cultures of HTM cells were
serum-starved for 16 h, pre-treated for 2 h with the MAPK inhibitors (10 μM) or with the TGFRI inhibitor, and then subjected for 16 h to
cyclic mechanical stress (5% elongation, one cycle per second) in the presence of the inhibitors (5 μM). A: Secreted IL-6 quantified by ELISA
after 16 h of mechanical stress is shown in the chart. B: Differential IL-6 mRNA expression compared to control-DMSO, calculated at 16 h
of mechanical stress. The asterisk indicates that p is less than 0.05, and the double asterisk denotes that p is less than 0.005. Statistical
significance between groups was assessed by the paired Student's t-test (n=3).
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330units [RFU] in IL-6-treated cultures versus 52.34±12.79 RFU
in  control  cultures,  p=0.042)  and  6  h  post  treatment
(393.44±132.45  RFU    in  IL-6-treated  cultures  versus
7.96±26.07 RFU in control cultures, p=0.034) compared to
control  levels.  To  identify  the  intracellular  pathways
participating in such activation, we repeated the experiment
in the presence of MAPK inhibitors. Whereas PD98059 and
SP600125  did  not  exert  any  major  effect,  SB202190
significantly decreased the percentage of induction in SEAP
activity compared to the control (394.75±74.2 RFU in vehicle-
treated  cultures  versus  168.43±53.8  RFU  in  SB202190-
treated  cultures,  p=0.012),  thus  suggesting  a  role  of  p38
MAPK in the upregulation of TGF-β1 by IL-6 (Figure 5B).
DISCUSSION
Our results indicate that TGF-β1 participates in the regulation
of the basal and the stretch-induced expression of IL-6 and
suggest the possible existence in cultured HTM cells of an
autocrine loop between IL-6 and TGF-β1. In addition, our data
suggest that p38 MAPK might play a contributing role in the
maintenance of such a loop. These findings support a potential
role of mechanical stress in regulating AH outflow through a
synergistic collaboration between MAPK and stretch-induced
cytokines.
The upregulation of IL-6 by TGF-β1 has been described
in other cell types including human fibroblasts, osteoblasts,
prostate cancer cells, and retinal pigmented epithelial cells
[21-29]. Our time-course experiments showed a progressive
accumulation  of  IL-6  in  the  culture  media  of  HTM  cells
exposed to TGF-β1. Levels of IL-6 mRNA were also found to
be increased at early times (up to 6 h), returning to control
levels after 16 h, thus indicating a transient effect of TGF-β1
on  IL-6  production.  Strikingly,  quantification  of  IL-6
promoter activity using a recombinant adenovirus expressing
the  reporter  gene,  SEAP,  under  the  IL-6  promoter  region
showed  no  difference  in  SEAP  activity  between  TGF-β1
treated  and  untreated  HTM  cultures  at  any  time  tested.
However, a gradual increase in SEAP activity was detected
over time in the untreated, control cultures, thus confirming
the efficiency of the selected IL-6 promoter region to mediate
the expression of the reporter gene. Upregulation of IL-6 is
controlled by the activity of several transcription factors with
known  consensus  sequences  in  the  IL-6  promoter  region
including IRF-1, AP-1, CRE, c/EBP, and NF-κB [30,31]. One
might  speculate  that  the  promoter  region  included  in  our
construct does not contain the binding sequence required for
a  particular  transcription  factor  activated  by  TGF-β1.
Although we cannot rule out the need of additional responsive
elements in HTM cells, transactivation of the IL-6 promoter
by TGF-β1 has been reported to be mediated via an AP-1
responsive element (−283/−277) in human lung fibroblasts
[22]. Such AP-1 binding site is contained within the promoter
region used in our experiments. Furthermore, increased IL-6
mRNA levels in response to TGF-β1 were also observed in
the presence of the transcription inhibitor, actinomycin D.
Thus, our results suggest that the high levels of expression of
IL-6 in response to TGF-β1 in HTM cells were not primarily
mediated by a transcriptional activation of IL-6.
A potential mechanism by which TGF-β1 can mediate the
observed increase in IL-6 is through mRNA stabilization.
Many short-lived mRNAs encoding proto-oncogenes, nuclear
transcription  factors,  and  cytokines  contain  adenylate/
uridylate  (AU)-rich  elements  (AREs),  which  are  usually
found  in  the  3′-untranslated  region  and  regulate  mRNA
stability. Stabilization of mRNA is a characteristic of short-
lived  cytokines  and  contributes  to  the  strong  and  rapid
induction  of  genes  in  the  inflammatory  response,  which
otherwise are targeted to degradation [32,33]. Indeed, IL-6
mRNA has been reported to rapidly be degraded in non-
stimulated  cells  [18].  Similarly,  our  own  results  show  a
Figure 5. Effect of IL-6 on the TGF-β1 promoter activity. Three independent primary cultures of HTM cells were infected with AdTGFβ1-
SEAP (m.o.i=20 pfu/cell) and serum-starved for 16 h at day 1 post-infection. A: Cells were incubated in serum-free media with IL-6 (100 ng/
ml). SEAP activity was assayed in the culture media at the indicated times. B: Cells were pre-treated for 2 h with the MAPK inhibitors and
then incubated in serum-free media with IL-6 (100 ng/ml) in the presence of the inhibitors (10 μM). SEAP activity in the culture media was
assayed at 6 h. The asterisk indicates that p is less than 0.05. Statistical significance between groups was assessed by the paired Student's t-
test (n=3).
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331progressive decline in IL-6 mRNA levels in untreated HTM
cells. Induction of IL-6 associated with mRNA stabilization
has been described in several cellular systems in response to
different compounds including TGF-β1 [17-20]. Additional,
more specific experiments aimed at monitoring the half-life of
IL-6 mRNA will be required to confirm the stabilization of
mRNA in HTM cells in response to TGF-β1 treatment.
MAPKs are known to be key regulators of the expression
of many cytokines and in responding to extracellular stimuli.
MAPKs are also known to play a crucial role in the response
to cyclic stretching in cells from tissues that are subjected to
this type of stress in physiologic conditions including the
vascular  endothelium,  pulmonary  epithelium,  kidney
podocytes,  and  cardiac  myocytes  [34-36].  Moreover,  our
previous studies, which used a static model of mechanical
stress, have shown fluctuations in the levels of expression and
phosphorylation of at least some MAPKs in HTM cells [37].
Therefore, we chose to investigate the potential participation
of MAPKs in the stretch-induced expression of IL-6. We
found that p38 MAPK and ERK1/2 pathways contribute to
IL-6  upregulation  in  stretched  HTM  cells  and  that  their
inhibition significantly attenuates IL-6 protein and mRNA
levels,  indicating  a  synergistic  collaboration  of  multiple
signaling in the induction of IL-6 by cyclic mechanical stress
in HTM cells.
One of the most interesting observations in our study was
that specific blockage of the TGF-β1 pathway using a TGF
type I activin receptor inhibitor significantly affected the basal
production of IL-6 and completely abrogated the increased
expression  of  IL-6  with  mechanical  stress.  These  results
clearly  demonstrate  a  key  role  for  TGF-β1  in  basal  IL-6
expression as well as the upregulated expression of IL-6 by
cyclic mechanical stress in HTM cells. Since p38 MAPK was
found to regulate both the TGF-β1 and the stretch-induced
expression of IL-6, it is likely that the observed effect of TGF-
β1 on the increased expression of IL-6 by mechanical stress
is also partly mediated through p38 MAPK. Although TGF-
β1 is known to regulate the expression of IL-6 [21-29] and IL-6
expression has been shown to be modulated by mechanical
stress in different cell types [38-43], this is the first time to our
knowledge  that  a  connection  between  both  events  is
established.
TGF-β1 has been reported to positively regulate its own
transcription  in  TM  cells  [44].  Here,  we  observed  that
treatment of HTM cells with exogenous IL-6 induced the
transcriptional activation of TGF-β1 promoter and that such
induction was impaired by blocking the p38 MAPK pathway.
A  similar  autocrine  loop  between  TGF-β1  and  IL-6  was
recently described in pancreatic stellate cells [21]. Altogether,
these findings open up the possibility that activation of TGF-
β1 by mechanical forces might act as an upstream signal
leading to increased IL-6 expression, which in turn might
upregulate the production of TGF-β1. We further propose that
p38 MAPK might be one of the factors regulating such an
autocrine loop between TGF-β1 and IL-6, although we do not
discard  the  possibility  of  the  synergistic  collaboration  of
multiple  MAPK  pathways  (in  fact,  our  data  suggest  this
possibility). Additional studies will be required to confirm the
existence of a TGF-β1/IL-6 loop in HTM cells in response to
mechanical stress.
In the short term, TGF-β1 and IL-6 potentially can have
a beneficial effect in regulating the flow of AH. Indeed, we
previously  showed  that  exogenous  administration  of  IL-6
produces an increase in outflow facility in porcine perfused
anterior segments as well as an increase in permeability in
cultured SC cells [9]. The existence of such a regulatory loop
could offer important biological advantages by increasing
redundancy in the mechanisms that modulate the expression
of cytokines in TM cells and, perhaps more importantly, by
providing a mechanism for amplification of relatively small
stress signals. However, the permanent activation of these two
pro-inflammatory  cytokines  can  ultimately  lead  to
undesirable  secondary  effects.  Dysregulation  of  IL-6  and
TGF-β1 has been linked to an array of inflammatory and
pathologic conditions including atherosclerosis, Alzheimer
disease,  and  rheumatoid  arthritis  [45-52].  Therefore,  we
anticipate the existence of a negative regulatory mechanism
aimed at preventing a chronic activation of the stress response
that might originate from the constitutive activation of such a
loop under normal tissue physiology.
It is important to mention that a constitutive activation of
the stress response controlled by an autocrine IL-1 feedback
loop has been described in the cells within the glaucomatous
outflow pathway [53]. In addition, a more recent study showed
an  altered  responsiveness  of  ERK,  p38  MAPK,  and  JNK
pathways  in  glaucomatous  TM  cells,  which  the  authors
postulated might be due to the fact that the pathways are
already maximally activated by the disease process [54]. In
this scenario, TM cells could be unable to modulate their gene
expression patterns and lose the flexibility to respond to the
environment. Similarly, failure of the feedback mechanism
controlling  the  TGF-β1/IL-6  loop  could  lead  to  a  related
disease phenotype.
In summary, we have described here that that TGF-β1
participates in the regulation of the basal and the stretch-
induced  expression  of  IL-6,  and  we  suggest  the  possible
existence of an autocrine loop between IL-6 and TGF-β1 in
cultured HTM cells. We also found that p38 MAPK might
play a contributing role in the maintenance of such a loop.
Additional  studies  aimed  at  understanding  the  effects  of
mechanical stress on the MAPK pathways and their potential
role in modulating the expression of TGF-β1 and IL-6 in HTM
cells using mechanical stress models would very likely help
to dissect the homeostatic molecular mechanisms involved in
the outflow pathway “sensing” and “responding” to changes
in IOP.
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